Streetbeat News

Products Services

SON

Sonoco announced a price increase of €60 per ton for uncoated recycled paperboard in Europe, with a £50 increase for the UK market. This adjustment is a response to market conditions.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:09 pm

STOK

Stoke Therapeutics announced promising Phase 1/2a end of study data for STK-001, showing significant reductions in convulsive seizure frequency in Dravet Syndrome patients. The data revealed 85% median reduction at 3 months and 74% at 6 months with 70mg doses. Open label extension studies showed durable seizure reductions and cognitive improvements over 12 months with 30mg and 45mg doses. STK-001 was well-tolerated, and the company plans to discuss registrational study design with regulatory agencies, aiming for initial doses of 70mg followed by 45mg. A webcast for analysts and investors is scheduled for 4:30 p.m. Eastern Time today.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:04 pm

ESPR

Esperion announced that data from the CLEAR Outcomes sub-groups will be presented in various formats, including poster presentations, a moderated session, and an Industry Expert Theatre at ACC.24.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:01 pm

VHAI

Vocodia has announced through a post on X that they are preparing for an exciting Q2 with a focus on innovation and growth. They hinted at upcoming announcements that will showcase their efforts to push boundaries and drive success.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 7:51 pm

VHAI

Vocodia has announced its focus on innovation and growth for Q2, teasing upcoming updates and expressing enthusiasm for future success.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 7:51 pm

MRK

Financial giants have shown a bullish stance on Merck & Co (NYSE:MRK) through options trading, with a notable lean towards calls over puts. Analysis of recent trades indicates a target price range of $120.0 to $135.0. The company, a major player in pharmaceuticals, has seen its stock price slightly increase to $123.86. Analyst ratings have varied, with a consensus target price of approximately $124.67, though opinions range from Overweight to Sell.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 7:46 pm

TSLA

Tesla Inc. has implemented a new policy requiring staff to install and demonstrate its driver-assistance technology, including Full Self-Driving, to customers before finalizing sales in North America. This directive, outlined in an internal memo by CEO Elon Musk, aims to ensure customers are familiar with the technology but is expected to slow down the delivery process.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 7:35 pm

MSFT

Microsoft Corp. (NASDAQ:MSFT) has finalized a partnership with game developer Toys for Bob, known for Crash Bandicoot and Spyro, to finance the development of an undisclosed game. This follows Toys for Bob's announcement of becoming an indie developer and leaving Microsoft-owned Activision. The partnership fuels speculation about the revival of popular franchises like Crash Bandicoot and Spyro. Microsoft's acquisition of Activision Blizzard brings major franchises under its umbrella, including Call of Duty and Halo.

Portfolio Pulse from Franca Quarneti

March 25, 2024 | 7:29 pm

TTWO

Take-Two Interactive Software Inc's (NASDAQ:TTWO) Grand Theft Auto VI faces potential delays, possibly pushing its release from 2025 to 2026 due to internal struggles at Rockstar Games over a return-to-office mandate. Initially announced for PlayStation 5 and Xbox Series in December 2023, the game's development has reportedly fallen behind schedule, leading to concerns about meeting the planned release window. Rockstar's in-office mandate, aimed at ensuring security and quality, has sparked frustration among employees and is cited as a significant factor in the potential delay.

Portfolio Pulse from Franca Quarneti

March 25, 2024 | 7:20 pm

NVO

Novo Nordisk (NYSE:NVO) has seen significant unusual options activity, with a bullish sentiment prevailing among financial giants. Analysis of options history revealed 26 unusual trades, with 61% bullish and 38% bearish. The trades include 10 puts valued at $1,362,610 and 16 calls valued at $832,150, targeting a price window of $80.0 to $175.0. Novo Nordisk, a leader in diabetes-care products, has its stock price up 0.49% at $129.4, with RSI indicators suggesting it may be approaching overbought. Analysts have set an average price target of $160.0 for NVO.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 7:16 pm